Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) (AMETHYST-DN)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01371747 |
|
Recruitment Status :
Completed
First Posted : June 13, 2011
Results First Posted : December 17, 2015
Last Update Posted : June 3, 2021
|
Sponsor:
Relypsa, Inc.
Information provided by (Responsible Party):
Vifor Pharma ( Relypsa, Inc. )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study determined the optimal starting dose of patiromer in treating hyperkalemia in participants with hypertension and diabetic nephropathy who were already receiving ACEI and/or ARB drugs, with or without spironolactone. This study also evaluated the efficacy and safety of patiromer and the long term use of patiromer.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Kidney Disease Hypertension Hyperkalemia | Drug: patiromer Drug: losartan Drug: spironolactone | Phase 2 |
RLY5016-205 was an open-label, randomized, dose ranging study to determine the optimal starting dose, efficacy and safety of patiromer in treating hyperkalemia in hypertensive patients with nephropathy due to type 2 diabetes mellitus (T2DM) who were already receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) drugs, with or without spironolactone.
The study consisted of the following periods:
- Screening: Up to 10 days (1 visit)
- Run-in for those who were not hyperkalemic at screening (Cohorts 1 and 2): up to 4 weeks (1 to 4 visits)
- Patiromer Treatment Initiation: first 8 weeks of patiromer treatment (a minimum of 10 visits)
- Patiromer Long-Term Maintenance: additional 44 weeks of patiromer treatment up to a total of one year (minimum of 11 additional visits)
- Follow-up (after patiromer discontinuation): 1 week (2 visits) OR 4 weeks (5 visits) depending on the final serum potassium level
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 324 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) Drugs, With or Without Spironolactone |
| Study Start Date : | June 2011 |
| Actual Primary Completion Date : | May 2013 |
| Actual Study Completion Date : | June 2013 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Hypertension
Drug Information available for:
Patiromer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Stratum 1: 8.4 g/d patiromer
Participants with baseline serum potassium > 5.0 to 5.5 mEq/L (milliequivalent)
|
Drug: patiromer
Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Other Names:
Drug: losartan losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1) Drug: spironolactone Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2) |
|
Experimental: Stratum 1: 16.8 g/d patiromer
Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
|
Drug: patiromer
Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Other Names:
Drug: losartan losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1) Drug: spironolactone Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2) |
|
Experimental: Stratum 1: 25.2 g/d patiromer
Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
|
Drug: patiromer
Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Other Names:
Drug: losartan losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1) Drug: spironolactone Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2) |
|
Experimental: Stratum 2: 16.8 g/d patiromer
Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
|
Drug: patiromer
Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
Other Names:
Drug: losartan losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1) Drug: spironolactone Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2) |
|
Experimental: Stratum 2: 25.2 g/d patiromer
Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
|
Drug: patiromer
Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
Other Names:
Drug: losartan losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1) Drug: spironolactone Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2) |
|
Experimental: Stratum 2: 33.6 g/d patiromer
Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
|
Drug: patiromer
Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
Other Names:
Drug: losartan losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1) Drug: spironolactone Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2) |
Primary Outcome Measures :
- Least Squares Mean Change in Serum Potassium From Baseline to Week 4 or Time of First Titration for Each Individual Starting Dose Group [ Time Frame: Baseline to Week 4 or First Titration which could occur at any scheduled study visit after patiromer initiation. ]Least square mean changes from Baseline to Week 4/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates.
Secondary Outcome Measures :
- Least Squares Mean Change in Serum Potassium From Baseline to Week 8 or Time of First Titration for Each Individual Starting Dose Group [ Time Frame: Baseline to Week 8 or First Titration which could occur at any scheduled study visit after patiromer initiation. ]Least squares mean changes from Baseline to Week 8/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates.
- Least Squares Mean Change in Serum Potassium From Baseline to Day 3 During the Treatment Initiation Period for Each Individual Starting Dose Group [ Time Frame: Baseline to Day 3 ]Least squares mean changes from Baseline to Day 3 were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates.
- Mean Change in Serum Potassium From Baseline to Week 52 During the Long-term Maintenance Period for Each Individual Starting Dose Group [ Time Frame: Baseline to Week 52 ]
- Mean Change in Serum Potassium From Week 52 or Last Patiromer Dose (if Occurred Before Week 52) to Follow-up Visits Plus 7 Days [ Time Frame: Week 52 or Last Patiromer Dose (if Occurred before Week 52) to Following up Visit Plus 7 Days ]
- Proportion of Participants Achieving Serum Potassium Levels Within 3.5 to 5.5 mEq/L at Week 8 for Each Individual Starting Dose Group [ Time Frame: Baseline to Week 8 ]
- Proportion of Participants Achieving Serum Potassium Levels Within 4.0 to 5.0 mEq/L at Week 8 for Each Individual Starting Dose Group [ Time Frame: Baseline to Week 8 ]
- Time to First Serum Potassium Measurement of 4.0 - 5.0 mEq/L During Treatment Initiation Period for Each Individual Starting Dose Group [ Time Frame: Baseline to Week 8 ]
- Proportions of Participants Achieving Serum Potassium Levels Within 3.8 to 5.0 mEq/L at Week 52 for Each Individual Starting Dose Group [ Time Frame: Baseline to Week 52 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age 30 - 80 years old at screening (S1)
- Type 2 diabetes mellitus (T2DM) diagnosed after age 30 which has been treated with oral medications or insulin for at least 1 year prior to S1
- Chronic kidney disease (CKD): estimated glomerular filtration rate (eGFR) 15 - < 60 mL/min/1.73m2 at screening based on central lab serum creatinine measurement (except for participants with hyperkalemia at S1), whose eligibility will be assessed based on local lab eGFR value)
-
Urine albumin/creatinine ratio (ACR):
- Cohorts 1 and 2: urine ACR ≥ 30 mg/g at S1 AND average urine ACR ≥ 30 mg/g at the beginning of Run-In Period (R0) based on up to three ACR values obtained starting at S1 and ending at the R0 Visit
- Cohort 3: not applicable
-
Local laboratory serum potassium (K+) values of:
- Cohorts 1 and 2: 4.3 - 5.0 mEq/L at S1; AND 4.5 - 5.0 mEq/L at R0; AND > 5.0 - < 6.0 mEq/L at randomization to patiromer (Baseline, T0 Visit)
- Cohort 3: > 5.0 - < 6.0 mEq/L at S1 OR at R0 after same day confirmation
- Must be receiving an ACEI and/or ARB for at least 28 days prior to screening
- Average systolic blood pressure (SBP) ≥ 130 - < 180 mmHg AND average DBP ≥ 80 - < 110 mmHg (sitting) at both screening and R0 (as applicable)
- Females of child-bearing potential must be non-lactating, must have a negative serum pregnancy test at screening, and must have used a highly effective form of contraception for at least 3 months before patiromer administration, during the study, and for one month after study completion
- Provide their written informed consent prior to participation in the study
Exclusion Criteria:
- Type 1 diabetes mellitus
- Central lab hemoglobin A1c > 12% at Screening 1 (S1) (except for Cohort 3 participants who are hyperkalemic at S1)
- Emergency treatment for T2DM within the last 3 months
- A confirmed SBP > 180 mmHg or diastolic blood pressure (DBP) > 110 mmHg at any time during SI or Run-In Period or at Baseline T0 Visit
- Central lab serum magnesium < 1.4 mg/dL (< 0.58 mmol/L) at screening (Cohort 3 participants will be evaluated based on local lab serum magnesium measurement)
- Central lab urine ACR ≥ 10000 mg/g at screening (except for Cohort 3 participants who are hyperkalemic at S1)
- Confirmed diagnosis or history of renal artery stenosis (unilateral or bilateral)
- Diabetic gastroparesis
- Non-diabetic chronic kidney disease
- History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders or major gastrointestinal surgery (e.g., large bowel resection)
- Current diagnosis of NYHA (New York Heart Association) Class III or IV heart failure
- Body mass index (BMI) ≥ 40 kg/m2
- Any of the following events having occurred within 2 months prior to screening: unstable angina as judged by the Principal Investigator (PI), unresolved acute coronary syndrome, cardiac arrest or clinically significant ventricular arrhythmias, transient ischemic attack or stroke, use of any intravenous cardiac medication
- Prior kidney transplant, or anticipated need for transplant during study participation
- Active cancer, currently on cancer treatment or history of cancer in the past 2 years except for non-melanocytic skin cancer which is considered cured
- History of alcoholism or drug/chemical abuse within 1 year
- Central lab liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST)] > 3 times upper limit of normal at S1 (except for Cohort 3 patients with hyperkalemia at S1, who will have local lab ALT and AST)
- Loop and thiazide diuretics or other antihypertensive medications (calcium channel blocker, beta-blocker, alpha-blocker, or centrally acting agent) that have not been stable for at least 28 days prior to screening or not anticipated to remain stable during study participation
- Current use of polymer-based drugs (e.g., sevelamer, sodium polystyrene sulfonate, colesevelam, colestipol, cholestyramine), phosphate binders (e.g., lanthanum carbonate), or other potassium binders, or their anticipated need during study participation
- Current use of lithium
- Use of potassium sparing medications, including aldosterone antagonists (e.g., spironolactone), drospirenone, potassium supplements, bicarbonate or baking soda in the last 7 days prior to screening
- Use of any investigational product within 30 days or 5 half-lives, whichever is longer, prior to screening
- Inability to consume the investigational product, or, in the opinion of the Investigator, inability to comply with the protocol
- In the opinion of the Investigator, any medical condition, uncontrolled systemic disease, or serious intercurrent illness that would significantly decrease study compliance or jeopardize the safety of the participant or affect the validity of the trial results
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01371747
Locations
Show 43 study locations
Sponsors and Collaborators
Relypsa, Inc.
Investigators
| Study Director: | Director Clinical Operations | Relypsa, Inc. |
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Relypsa, Inc. |
| ClinicalTrials.gov Identifier: | NCT01371747 |
| Other Study ID Numbers: |
RLY5016-205 2011-000165-12 ( EudraCT Number ) |
| First Posted: | June 13, 2011 Key Record Dates |
| Results First Posted: | December 17, 2015 |
| Last Update Posted: | June 3, 2021 |
| Last Verified: | May 2021 |
Keywords provided by Vifor Pharma ( Relypsa, Inc. ):
|
Hyperkalemia Chronic Kidney Disease Treatment of Hyperkalemia Hypertension Diabetic Nephropathy |
Additional relevant MeSH terms:
|
Kidney Diseases Renal Insufficiency, Chronic Diabetic Nephropathies Hypertension Hyperkalemia Vascular Diseases Cardiovascular Diseases Urologic Diseases Renal Insufficiency Diabetes Complications Diabetes Mellitus Endocrine System Diseases Water-Electrolyte Imbalance Metabolic Diseases |
Losartan Spironolactone Anti-Arrhythmia Agents Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action Mineralocorticoid Receptor Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Diuretics, Potassium Sparing Diuretics Natriuretic Agents |